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Abstract
Background: Metastasis is the most frequent cause of treatment failure and death in colorectal cancer. Early detection of
tumors and metastases is crucial for improving treatment strategies and patient outcome. Development of reliable
biomarkers and simple tests routinely applicable in the clinic for detection, prognostication, and therapy monitoring is of
special interest. We recently identified the novel gene Metastasis-Associated in Colon Cancer 1 (MACC1), a key regulator of
the HGF/Met-pathway. MACC1 is a strong prognostic biomarker for colon cancer metastasis and allows identification of
high-risk subjects in early stages, when determined in patients’ primary tumors. To overcome the limitation of a restricted
number of molecular analyses in tumor tissue, the establishment of a non-invasive blood test for early identification of high-
risk cancer patients, for monitoring disease course and therapy response is strongly needed.
Methodology/Principal Findings: For the first time, we describe a non-invasive assay for quantification of circulating
MACC1 transcripts in blood of more than 300 colorectal cancer patients. MACC1 transcript levels are increased in all disease
stages of the cancer patients compared to tumor-free volunteers. Highest MACC1 levels were determined in individuals with
metastases (all P,0.05). Importantly, high MACC1 levels correlate with unfavorable survival (P,.0001). Combining MACC1
with circulating transcripts of the metastasis gene S100A4, a transcriptional target of the Wnt/b-catenin-pathway, improves
survival prediction for newly diagnosed cancer patients.
Conclusion/Significance: This blood-based assay for circulating MACC1 transcripts, which can be quantitated on a routine
basis, is clinically applicable for diagnosis, prognosis, and therapeutic monitoring of cancer patients. Here we demonstrate
the diagnostic and prognostic value of circulating MACC1 transcripts in patient plasma for metastasis and survival. Since
MACC1 represents a promising target for anti-metastatic therapies, circulating MACC1 transcripts may prove to be an ideal
read-out for monitoring therapeutic response of future interventions targeting MACC1-induced metastasis in cancer
patients.
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Introduction
Metastasis is the most frequent cause of treatment failure and
death in colorectal cancer. Early detection of tumors and
metastases is crucial for improving treatment strategies and patient
outcome. Development of reliable biomarkers and simple tests that
are routinely applicable in the clinic for detection, prognostication,
and therapy monitoring is of special interest.
We recently identified the novel gene Metastasis-Associated in
Colon Cancer 1 (MACC1) [1–3]. MACC1 is a new prognostic
biomarker for colon cancer metastasis and metastasis-free survival
when determined in patients’ primary tumors. MACC1 levels in
the primary tumors were found to be significantly higher in
cancers that metachronously developed distant metastases com-
pared to those which did not metastasize within a 12-year follow-
up. The predictive value of the biomarker on whether a tumor will
metastasize or not was 74% and 80% respectively. The 5-year-
survival rate was 80% for patients with low MACC1, compared to
15% for patients with high MACC1 expression in their primary
tumors. MACC1 is a predictor for colorectal cancer metastasis
independent of tumor stage, age, sex, tumor infiltration, nodal
status and lymph vessel invasion, and thus allows identification of
subjects at high risk for metastasis in early stages [1]. This makes
MACC1 an important prognostic gene in clinical practice.
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Furthermore, we found that MACC1 acts a key regulator of the
HGF (hepatocyte growth factor)/Met-pathway, which is crucial in
colorectal cancer for tumor progression and metastasis formation
[1,2,4].
Several groups confirmed meanwhile a correlation of high
MACC1 expression in the tumor to progression, metastasis,
survival, and therapy response in colorectal cancer (CRC) [5–9].
The role of MACC1 as a biomarker for cancer progression and
survival was meanwhile also reported for other solid cancers, such
as gastric [10], lung [11,12], hepatocellular [13,14] and ovarian
cancer [15].
Molecular analyses in tumor tissue, e.g. needed for disease
prognosis in the context of metastasis formation and survival, are
limited to a restricted number of available tissue samples. To
overcome this limitation, the establishment of a non-invasive
MACC1-based blood test for early identification of high risk
cancer patients and for monitoring of the disease course as well as
of therapy response is therefore strongly needed.
Here, for the first time, we developed a non-invasive assay for
MACC1 transcript levels in plasma. We analyzed the diagnostic
value of MACC1 levels for detection of tumors and metastases in
colon and rectal cancer patients, and its prognostic value for
overall survival (survival) of these patients. Furthermore, we
evaluated the benefit of combining MACC1 with a further
metastasis gene, S100A4, for improved prediction of disease
prognosis [16–18].
Materials and Methods
Objective
The metastasis-inducing gene MACC1 is a strong prognostic
biomarker for colon cancer metastasis and allows identification of
high-risk subjects in early stages, when determined in patients’
primary tumors. To overcome the limitation of a restricted
number of molecular analyses in tumor tissue, we aimed at the
establishment of a non-invasive MACC1-based blood test for early
identification of high risk cancer patients and for monitoring the
disease course.
Participants
For colon and rectal cancer patients’ characteristics see Tables 1,
2, 3. Consecutive patients with colon or rectal cancer who were
seen at the Robert Ro¨ssle Cancer Hospital, Charite´ University
Medicine Berlin, during 2006 until 2007 for inpatient or
outpatient care and who gave their written informed consent to
take part in our tumor biobank were enrolled.
Patients’ data for histopathological characterization of the
tumor (including tumor infiltration, lymph node status, metastasis,
grading, lymphatic vessels infiltration, blood vessels infiltration,
residual tumor), for treatment and survival were available from the
tumor bank of the Charite´ Comprehensive Cancer Center.
Histological tumor staging was performed by routine pathology.
Exclusion criteria were other malignancies during history or
follow-up. We analyzed 312 blood samples of colon (n = 151) and
rectal (n = 161) cancer patients (Tables 1, 2, 3).
Blood samples were taken at the day of diagnosis from newly
diagnosed patients with a primary tumor without or with
synchronous metastases or from patients who developed metasta-
ses metachronously after R0-resection of the primary tumor.
Exception: Patients with newly diagnosed locally advanced rectal
cancer, who received neoadjuvant short-course radiation or long-
term radiochemotherapy (n = 16). Here, blood samples were taken
after neoadjuvant treatment of the primary tumor. For patients
receiving short-course radiation, the interval between the end of
the treatment and blood taking was 3 to 6 days. We did not find
significantly different MACC1 transcript levels between the
treated (n = 16) and the non-treated rectal cancer patients (n = 23).
Blood samples from the cohort of follow-up patients were taken
exclusively during the follow-up period (median 975 and 1280
days after primary diagnosis; median 807 and 853 days follow-up
after blood taking for colon and rectal cancer, respectively).
The plasma controls derived from two independent cohorts of
volunteers (n = 54). Recruitment of the volunteers was supported
by Klaus Sperber, Medical Practioner, Berlin, and by Ursula
Plo¨ckinger, Charite´ Campus Virchow Klinikum, Berlin. All
volunteers must be tumor-free and without a history of oncological
diseases. We did not find significantly different MACC1 levels with
respect to gender, age, or between the two cohorts.
Newly diagnosed colorectal cancer patients with a primary
tumor with or without synchronous metastases were grouped due
to their chronological examination in a test-set (n = 36) and a
validation-set (n = 35) for determination of the diagnostic value of
circulating MACC1 transcripts (Table 4).
Plasma Preparation
First, we examined optimal conditions for blood taking, storage,
and plasma separation. Following blood taking of healthy
volunteers (n = 12), EDTA-blood was kept at room temperature
or at 4uC. Plasma separation was done either immediately, or 7,
24, 48, and 72 hours after blood taking (10 analyses per volunteer).
RNA was isolated and MACC1-specific quantitative real-time
RT-PCR was performed in duplicates (Fig. 1A). MACC1
transcript levels served as read-out. We found no alterations of
MACC1 levels when the plasma separation was carried out during
the first 24 hours (either cooled or kept at room temperature).
Based on these findings, plasma was separated from cooled
EDTA-blood at the same day within 7 hours post blood taking.
Procedure for plasma separation was as previously described [18].
Blinded samples, neither colon nor rectal cancer, nor disease stage
was disclosed during analysis, were stored at 280uC.
RNA and Quantitative Real-Time RT-PCR
Isolation of total RNA was performed as previously described
[18]. Quantitative real-time RT-PCR was carried out at 30 sec
95uC, 456(10 sec 95uC, 10 sec 62uC, 10 s 72uC), melting curve
40uC to 95uC, by using the LightCycler (DNA Master Hybrid-
ization Probes kit, Roche Diagnostics) as previously described [1].
The following primers and probes were used amplifying a 136 bp
MACC1-specific PCR product: forward primer 59-TTCT-
TTTGATTCCTCCGGTGA-39, reverse primer 59-ACTCT-
GATGGGCATGTGCTG-39, FITC-probe 59-GCAGACTTC-
CTCAAGAAATTCTGGAAGATCTA-39, LCRed640-probe 59-
AGTGTTTCAGAACTTCTGGACATTTTAGACGA-39 (syn-
theses of primers and probes: BioTeZ and TIB MolBiol, Berlin,
Germany). The calibrator cDNA was employed in serial dilutions
simultaneously in each run, derived from the cell lines SW620.
Authentification of the cell line was performed by short tandem
repeat (STR) genotyping (DSMZ Braunschweig, Germany). STR
genotype was consistent with the published genotype for this cell
line (ATCC, CCL-227). S100A4-specific quantitative real-time
RT-PCR was carried as previously described [18]. mRNA
expression of a blood sample is given as percentage of the mRNA
expression of a defined calibrator sample, which was set 100%.
Each sample was run in duplicate, the means are depicted.
Ethics
All blood specimens from patients and tumor-free volunteers
were obtained with informed written consent in accordance to the
MACC1 Transcripts in Cancer Patient Plasma
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International Conference on Harmonisation and with approval of
the local IRB.
Statistical Methods
Differences between groups in terms of MACC1 transcript
levels in plasma were tested by using non-parametric Wilcoxon-
Mann-Whitney tests (dependent on the distribution of normality):
tumor-free volunteers vs. patients with primary tumors without
and with synchronous metastases, to patients with metachronous
metastases, and to follow-up patients; patients with tumors vs.
those with tumors and metastases. In case of small samples, greater
differences in sample sizes, large but unbalanced groups, data sets
containing ties, or sparse data, tests were carried out in an exact
version. We considered P,0.05 to be significant. All numerical
calculations were performed with SPSS, version 18.
To define the diagnostic value of circulating MACC1 transcripts
in plasma, sensitivity and specificity were calculated with a fourfold
table for colorectal cancer (test- and validation-set), colon, and
rectal cancer patients, who were newly diagnosed with a primary
tumor without or with synchronous metastases compared to the
blood samples of 54 tumor-free volunteers. In accordance with
their chronological examination and initial blood taking patients
were grouped in a test-set and validation-set. We began with a test-
set of newly diagnosed CRC patients (n = 36), determined the
optimal cut-off value of MACC1 (sensitivity 75%, specificity 76%),
and applied this cut-off value for the validation-set of CRC
patients (n = 35). Sensitivity and specificity were 77% and 76%,
respectively. When combining all newly diagnosed CRC patients,
sensitivity and specificity were 76%. When analyzing colon and
rectal cancer patients separately, sensitivity was 77% for colon
cancer and 76% for rectal cancer. Specificity was 89% for colon
cancer and 76% for rectal cancer, respectively.
Table 1. Colorectal cancer patients characteristics and circulating MACC1 transcript levels in plasma.
Tumor-free
volunteers
Newly diagnosed
primary tumor
without metastasis
Newly diagnosed
primary tumor
with synchronous
metastasis
Newly diagnosed
metachronous
metastasis Follow-up
All cancer
patients
Blood samples, n 54 51 20 11 230 312
UICC I, % 12 0 18 27 22
UICC II, % 27 0 0 27 24
UICC III, % 61 0 72 45 46
UICC IV, % 0 100 9 2 8
Adjuvant therapy 15/51 – 6/11 129/230 150/312
Follow up, median, days 850 461 711 840 840
Age, median (range), years 61 (27–87) 68 (19–84) 65 (38–78) 64 (48–74) 63 (18–81) 64 (18–84)
Sex, male/female 43/11 35/16 14/6 6/5 145/85 200/112
MACC1 mRNA expression,
% calibrator (median)
0.224 0.610 0.937 0.700 0.490 0.520
P, vs tumor-free volunteers ,.001 ,.001 ,.001 ,.001 ,.001
doi:10.1371/journal.pone.0049249.t001
Table 2. Colon cancer patients characteristics and circulating MACC1 transcript levels in plasma.
Tumor-free
volunteers
Newly diagnosed
primary tumor
without metastasis
Newly diagnosed
primary tumor
with synchronous
metastasis
Newly diagnosed
metachronous
metastasis Follow-up
All cancer
patients
Blood samples, n 54 12 10 4 125 151
UICC I, % 42 0 0 26 25
UICC II, % 42 0 0 27 26
UICC III, % 7 0 75 43 39
UICC IV, % 0 100 25 3 10
Adjuvant therapy 2/12 – 1/4 50/125 53/151
Follow up, median, days 935 302 590 807 805
Age, median (range), years 61 (27–87) 66 (51–75) 67 (38–78) 59 (48–62) 63 (34–81) 63 (34–81)
Sex, male/female 43/11 10/2 6/4 1/3 71/54 88/63
MACC1 mRNA expression,
% calibrator (median)
0.224 0.780 2.249 0.968 0.504 0.516
P, vs tumor-free volunteers ,.001 ,.001 .016 ,.001 ,.001
doi:10.1371/journal.pone.0049249.t002
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For survival analysis of newly diagnosed and of all CRC
patients, Kaplan Meier curves in combination with log rank test
were used. Those CRC patients were included in this analysis
where both markers, MACC1 and S100A4, could be determined
(n = 294). The cut-off value of MACC1 and the cut-off value of
S100A4 were the median of the investigated groups (primary
diagnosis or all patients), respectively. Calculations were per-
formed with SPSS, version 18.
Results
Quantification of Circulating MACC1 Transcripts in
Human Plasma
We initially identified optimal conditions for plasma processing
and MACC1 transcript quantification after blood taking. Plasma
separation and subsequent MACC1 analyses were performed
immediately or 7, 24, 48, and 72 hours after blood taking from
tumor-free volunteers (n = 12; 10 aliquots per volunteer), either
4uC-cooled or left at room temperature (Fig. 1A). Increased
MACC1 levels were measured due to hemolysis after 48 and 72
hours following taking blood. To determine the basal levels of
circulating MACC1 transcripts in tumor-free volunteers and
colorectal cancer patients, we subsequently separated plasma from
4uC-cooled blood samples within the first 7 hours after blood
taking.
Circulating MACC1 Transcripts in Plasma of Tumor-free
Volunteers
We analyzed the basal MACC1 levels of tumor-free volunteers
in two independent cohorts (n = 34 and n = 20, respectively;
Fig. 1B). MACC1 transcripts were detected in all samples, without
significant differences between the two cohorts. All tumor-free
volunteers were combined for subsequent analyses (median 0.224
MACC1 mRNA expression/% calibrator).
Circulating MACC1 Transcripts in Plasma Discriminate
Tumor-free Volunteers and Colorectal Cancer Patients
Next, we analyzed MACC1 levels in plasma of colon (n = 151)
and rectal (n = 161) cancer patients (patients’ characteristics:
Tables 1, 2, 3). To evaluate the diagnostic value of circulating
MACC1 transcripts in plasma, we compared newly diagnosed
CRC patients with a primary tumor with or without synchronous
metastases (n = 71) with tumor-free volunteers (n = 54) and
calculated sensitivity and specificity with a fourfold table. We
began with a test-set of newly diagnosed CRC patients (n = 36;
sensitivity 75%; specificity 76%), and applied the calculated
optimal cut-off value for the validation-set of newly diagnosed
CRC patients (n = 35; sensitivity 77%; specificity 76%). When
combining all CRC patients newly diagnosed, sensitivity and
specificity were 76% (Table 4). When analyzing colon and rectal
cancer patients separately, sensitivities were 77% and 76%, and
specificities were 89% and 76%, respectively. Thus, MACC1
Table 3. Rectal cancer patients characteristics and circulating MACC1 transcript levels in plasma.
Tumor-free
volunteers
Newly diagnosed
primary tumor
without metastasis
Newly diagnosed
primary tumor
with synchronous
metastasis
Newly diagnosed
metachronous
metastasis Follow-up
All cancer
patients
Blood samples, n 54 39 10 7 105 161
UICC I, % 3 0 29 27 19
UICC II, % 23 0 0 27 23
UICC III, % 74 0 71 47 52
UICC IV, % 0 100 0 0 6
Adjuvant therapy 13/39 – 5/7 79/105 97/161
Follow up, median, days 848 994 751 853 818
Age, median (range), years 61 (27–87) 67 (19–84) 63 (59–72) 67 (49–74) 62 (18–77) 64 (18–84)
Sex, male/female 43/11 25/14 8/2 5/2 74/31 112/49
MACC1 mRNA expression,
% calibrator (median)
0.224 0.559 0.829 0.621 0.490 0.520
P, vs tumor-free volunteers ,.001 ,.001 .002 ,.001 ,.001
doi:10.1371/journal.pone.0049249.t003
Table 4. Diagnostic value of circulating MACC1 transcript levels in plasma of newly diagnosed colorectal, colon, and rectal cancer
patients with a primary tumor with or without synchronous metastasis.
Cancer Samples Optimal cut-off Sensitivity Specificity
n MACC1 mRNA expression, % calibrator % %
Colorectal 71 0.398 76 76
Colon 22 0.503 77 89
Rectal 49 0.398 76 76
Optimal cut offs were calculated with a fourfold table.
doi:10.1371/journal.pone.0049249.t004
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transcript levels in plasma supports the identification of individuals
bearing colon and rectal cancer.
We detected MACC1 transcripts in plasma of all cancer
patients. We found significantly higher MACC1 levels in colon,
rectal, and colorectal (combined) cancer patients compared to
tumor-free individuals (all P,.001; Fig. 1C). We observed no
significant variations of MACC1 levels due to age, sex, or between
the tumor stages I, II and III.
High Circulating MACC1 Transcript Levels in Plasma of
Metastasized Colorectal Cancer Patients
To evaluate the relevance of circulating MACC1 transcripts in
plasma with respect to metastasis formation, patients were
classified according to disease stage: patients with a primary
tumor without synchronous metastasis (stages I-III; n = 51 for
colorectal, n = 12 for colon, and n = 39 for rectal cancer patients);
patients with a primary tumor and synchronous metastasis (stage
IV; n = 20 for colorectal, n = 10 for colon, and n = 10 for rectal
cancer patients); and individuals with metachronous metastasis
after R0-resection of the primary tumor (n = 11 for colorectal,
n = 4 for colon, and n = 7 for rectal cancer patients) (Tables 1, 2,
3). Blood was taken at the day of diagnosis. Additionally, we also
included follow-up patients (n = 230 for colorectal, n = 125 for
colon, and n = 105 for rectal cancer patients; Tables 1, 2, 3).
MACC1 levels were significantly higher in each disease stage of
colon and rectal cancer compared with tumor-free volunteers
(Fig. 2A–C). Remarkably, clearly increased MACC1 levels were
detected in newly diagnosed cancer patients with synchronous
metastasis (stage IV), compared to cancer patients without distant
metastases (stages I-III): for colorectal (Fig. 2A), colon (Fig. 2B),
and rectal cancer (Fig. 2C), medians 0.937, 2.249, and 0.829
MACC1 mRNA expression/% calibrator in metastasized patients,
compared to 0.61, 0.78, and 0.559 MACC1 mRNA expression/%
calibrator in patients without distant metastases (P= .006,
P= .176, and P= .041 for colorectal, colon, and rectal cancer
patients, respectively). Thus, quantitative determination of
MACC1 transcripts in patient blood is of diagnostic value with
respect to metastasis.
High Circulating MACC1 Transcript Levels in Plasma of
Colorectal Cancer Patients is Associated with Shorter
Survival
Next, we evaluated the prognostic impact of circulating
MACC1 transcripts in plasma. We began the analysis of
circulating MACC1 levels with respect to the survival of newly
diagnosed CRC patients with a primary tumor with or without
synchronous metastases (blood samples were taken at the day of
diagnosis) (Fig. 3A). The cut-off value used was the median of the
measured MACC1 levels in this patient cohort (0.670 MACC1
mRNA expression/% calibrator). In accordance to this cut-off,
patients were classified as low or high MACC1 expressors.
Interestingly, those newly diagnosed patients with low MACC1
levels (,cut-off) demonstrated a significantly longer survival time
than patients with high MACC1 levels (.cut-off) (P= .003;
Fig. 3A). Thus, circulating MACC1 transcript levels in plasma
Figure 1. Circulating MACC1 transcript levels in plasma
discriminate cancer patients from tumor-free volunteers. A.
Plasma separation conditions for determination of circulating MACC1
transcripts. Plasma separation of samples from tumor-free volunteers
(n = 12) was done immediately, 7, 24, 48, and 72 hours after taking
blood, either from blood samples kept at 4uC or at room temperature.
Subsequently, plasma was generated within the first 7 hours from 4uC-
cooled blood. B. MACC1 transcripts in plasma of tumor-free volunteers
(n = 54). No difference in MACC1 transcript levels were found in two
independently analyzed cohorts of tumor-free volunteers (n = 34 and
n=20, respectively). C. MACC1 transcripts in plasma of all colorectal
cancer patients (n = 312). All patient cohorts bearing colorectal, colon
(n = 151), or rectal (n = 161) cancer expressed significantly higher
MACC1 transcript levels than tumor-free volunteers (P,.001 for all
comparisons).
doi:10.1371/journal.pone.0049249.g001
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Figure 2. Circulating MACC1 transcripts in colorectal, colon, and rectal cancer patient plasma. A, B, C. All colorectal (A, n = 312), colon (B,
n = 151), and rectal (C, n = 161) cancer patient sub-cohorts showed significantly higher circulating MACC1 transcript levels than tumor-free volunteers
(n = 54). Higher MACC1 levels were also found for colorectal (P= .006; A) and rectal (P= .041; C) cancer patients with synchronous metastases (n = 20
and n= 10, respectively) compared to patients without distant metastases (n = 51 and n= 39, respectively). Box plot analysis, based on quantitative
real-time RT-PCR.
doi:10.1371/journal.pone.0049249.g002
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when determined at the day of diagnosis, are of prognostic value
for the survival of newly diagnosed patients.
Next, we wished to analyze on whether a prognostic impact of
MACC1 transcripts holds true for the cohort of all CRC patients,
including the follow-up patients. The cut-off value used was the
median of the measured MACC1 levels of all CRC patients (0.518
MACC1 mRNA expression/% calibrator). Based on this cut-off,
all CRC patients were grouped as low or high MACC1 expressors.
Remarkably, we could confirm our finding from the group of
newly diagnosed patients also for all CRC patients analyzed:
patients with low MACC1 levels (,cut-off) showed a significantly
longer survival time than patients with high MACC1 levels (.cut-
off) (P,.0001; Fig. 3B). Thus, levels of circulating MACC1
transcripts in CRC patient plasma are of prognostic value with
respect to patient survival.
Combination of Circulating MACC1 and S100A4
Transcript Levels in Plasma Improves Survival Prediction
for Colorectal Cancer Patients
To further improve prediction of survival, we added the
metastasis gene S100A4, a target of the Wnt/b-catenin-pathway,
Figure 3. Survival of CRC patients based on circulating transcript levels of MACC1 or a combination of MACC1 and S100A4. A, B.
Kaplan-Meier analysis for newly diagnosed (A, n = 49) and all (B, n = 294) CRC patients, based on MACC1 alone (A, low MACC1 n= 24, high MACC1
n= 25; B, low MACC1 n= 147, high MACC1 n=147). Newly diagnosed CRC patients (A) as well as all CRC patients (B) with high circulating MACC1
transcript levels demonstrated shorter survival when compared with patients demonstrating low MACC1 levels (P= .003 and P,.0001, respectively).
C, D. Kaplan-Meier analysis for newly diagnosed (C, n = 49) and all (D, n = 294) CRC patients, based on a combination of MACC1 and S100A4. Newly
diagnosed CRC patients (C) and all CRC patients (D) were classified into groups of low expressors of both genes (n = 13 and n= 85, respectively), of
patients with high S100A4 levels (n = 25 and n=147, respectively), of patients with high MACC1 levels (n = 25 and n=147, respectively), or with high
expression of both biomarkers (n = 14 and n=85, respectively). For newly diagnosed patients (C), survival was reduced with increasing levels of
circulating transcripts of S100A4, of MACC1, or of both. Expression induction of either MACC1 or S100A4 or of both biomarkers correlated to reduced
patients survival.
doi:10.1371/journal.pone.0049249.g003
MACC1 Transcripts in Cancer Patient Plasma
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e49249
to this MACC1 analysis. We had chosen these metastasis
biomarkers for combination, since they address most relevant
signaling pathways in colorectal cancer progression and metastasis:
MACC1 - a key regulator of the HGF/Met signaling pathway,
and S100A4– a transcriptional target gene of the Wnt/b-catenin
signaling pathway. So far, no cross regulation of these two
metastasis-associated genes - MACC1 and S100A4 - is known.
Furthermore, we previously reported the diagnostic and
prognostic value of S100A4 transcripts in plasma [18]. Here,
individuals with low S100A4 plasma levels also showed a longer
survival (Fig. S1A,B).
We first addressed the question on whether the combination of
both biomarkers, circulating transcripts of MACC1 and of
S100A4, might improve the prognostic value of MACC1 alone
in the cohort of newly diagnosed CRC patients. The cut-off values
used were the median of the measured MACC1 levels in this
patient cohort (0.670 MACC1 mRNA expression/% calibrator) as
well as the median of the measured S100A4 levels in this patient
cohort (0.435 S100A4 mRNA expression/% calibrator). In
accordance to these cut-off values, patients were classified as low
expressors of both genes, as high expressors of S100A4, as high
expressors of MACC1, or as high expressors of both genes.
Patients who showed low circulating levels of MACC1 and of
S100A4, had the longest survival times. Reduced survival was then
observed for patients with high S100A4 levels, followed by patients
with high MACC1 levels. Shortest survival times were found for
patients with both biomarkers highly expressed (Fig. 3C). Thus, for
newly diagnosed patients, the combination of high MACC1 and
high S100A4 levels improved survival prediction, compared to
high MACC1 levels alone.
We then evaluated this combinatorial MACC1 and S100A4
approach with respect to survival for all CRC patients, including
the follow-up patients. The cut-off values used were the median of
the measured MACC1 levels for all CRC patients (0.518 MACC1
mRNA expression/% calibrator) as well as the median of the
measured S100A4 levels for all CRC patients (0.421 S100A4
mRNA expression/% calibrator). In accordance to these cut-off
values, all CRC patients were classified as low expressors of both
genes, as high expressors of S100A4, as high expressors of
MACC1, or as high expressors of both genes. As observed for the
newly diagnosed patients, also all CRC patients who showed low
circulating levels of MACC1 and of S100A4, had the longest
survival times. Expression induction of either MACC1 or S100A4
or of both biomarkers correlated to reduced patients survival
(Fig. 3D).
In addition, we also compared the survival of patients with low
levels of MACC1 and of S100A4 or with only one marker (either
MACC1 or S100A4) increased with the survival of those patients
who showed both MACC1 and S100A4 elevated. We found a
significantly shorter survival for patients with high plasma levels of
both biomarkers. This was observed for the cohort of newly
diagnosed patients (P,.0001; Fig. S2A) as well as for all CRC
patients analyzed (P= .001; Fig. S2B).
Discussion
Here we report the development of the first blood-based assay
for the metastasis-inducing gene MACC1, which is a prognostic
biomarker for colon cancer metastasis as well as for tumor
progression and survival in a variety of solid cancers. This assay for
circulating MACC1 transcripts, which can be quantitated on a
routine basis, is clinically applicable for diagnosis, prognosis, and
therapeutic monitoring of cancer patients. Levels of circulating
MACC1 transcripts are significantly higher in cancer patients
compared to tumor-free volunteers. Remarkably, highest levels of
circulating MACC1 transcripts were determined in individuals
with metastases, demonstrating the diagnostic value of circulating
MACC1 transcripts in patient plasma with respect to metastasis
formation. Most importantly, high MACC1 levels – prospectively
determined - correlate with unfavorable survival of the patients
underlining the prognostic value of circulating MACC1 tran-
scripts.
Detection of cell-free mRNA in blood as ‘‘liquid biopsies’’
allows real-time monitoring of disease progress, prognosis, and
therapeutic response [19]. Numerous studies describe transcript
detection of circulating cell-free RNA in plasma and serum of
patients suffering from a variety of solid cancers, including thyroid,
lung, gastric, breast and uterine cervical cancer, and its use for
prognosis of the disease course [20–29]. Stability of circulating
cell-free RNA is ensured by exosomes (microparticles, microves-
icles, multivesicles) protecting it from degradation [30,31].
Particularly for circulating plasma RNA from colon cancer
patients it is reported that this cell-free RNA is confined in
mRNA-enriched vesicle-like structures [32]. Several circulating
transcripts have already been reported to be useful for diagnosis
and prognosis for colorectal cancer; e.g. hTERT [33], b-catenin
[34], thymidylate synthase [35], and LISCH7 [36]. Particularly
CEA [37,38], also in combination with markers such as CK19,
CK20, hTERT, TIMP-1, miR141 [39–41], is recognized as
potential aid in early detection of CRC, as prognostic marker for
recurrence, and also as predictive biomarker with respect to
therapy response. Testing the combination of both, CEA and
MACC1, might outperform these features.
Our new findings of circulating MACC1 transcripts in plasma
of colorectal cancer patients for diagnosis and prediction of
survival are in line with those that we reported previously based on
the quantification of mRNA expression in colorectal cancer tissues
with respect to disease prognosis [1]. Subsequently, several groups
validated the link of high MACC1 expression in colorectal cancer
tissue to advanced disease (e.g. [5,7,8]). Thus, the employment of
the biomarker MACC1 for patient stratification might be
extended from tissues to this blood-based assay allowing repeated
measurements of circulating MACC1 transcript levels.
The combination of the two metastasis-inducing genes,
MACC1 - a key regulator of the HGF/Met signaling pathway
[1], with S100A4– a transcriptional target gene of the Wnt/b-
catenin signaling pathway [16], improves survival prediction for
newly diagnosed colorectal cancer patients. S100A4 has been
demonstrated to act as a metastasis-inducing gene [17,42,43].
Furthermore, S100A4 has been shown to be a prognostic
biomarker when determined in colorectal cancer tissues by
qRT-PCR and immunohistochemistry [16,44–48]. We have
recently demonstrated the diagnostic and prognostic value of
circulating S100A4 transcripts in colorectal cancer and in gastric
cancer patients [18]. Thus, combining biomarkers addressing
different, but most relevant signaling pathways in colorectal cancer
progression enhances the power of patient survival prediction.
The metastasis-inducing MACC1 is a master regulator of the
HGF/Met signaling pathway transcriptionally controlling the gene
for the receptor tyrosine kinase Met [1,6,49,50], which already
was evaluated as therapeutic target in clinical trials [50].
Therefore, MACC1 represents a most promising target for anti-
metastatic therapies. In conclusion, this clinically applicable blood-
based assay for circulating MACC1 transcripts in cancer patient
plasma allows the prognosis of metastasis and survival, but may
also prove to be an ideal read-out for monitoring therapeutic
response of future interventions targeting MACC1-induced
metastasis in cancer patients.
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Supporting Information
Figure S1 Survival of CRC patients based on circulating
S100A4 transcript levels. Kaplan-Meier analysis for newly
diagnosed (A) and all (B) CRC patients, based on S100A4. Patients
with high circulating S100A4 transcript levels demonstrated
shorter survival (P= .112 and P= .082, respectively).
(TIF)
Figure S2 Survival of CRC patients based on circulating
transcript levels of a combination of MACC1 and
S100A4. Kaplan-Meier analysis for newly diagnosed (A) and all
(B) CRC patients. A. Newly diagnosed CRC patients with low
levels of MACC1 and S100A4, or with only one marker (either
MACC1 or S100A4) increased (n = 35), had a significantly better
survival than patients with both markers elevated (n = 14,
P,.0001). B. All CRC patients with low levels of MACC1 and
S100A4, or with only one marker (either MACC1 or S100A4)
increased (n = 209), also demonstrated significantly better survival,
when compared to patients with both markers elevated (n = 85,
P= .001).
(TIF)
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